

Presentation	Supplier Name	Market Segment	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
			Bivalent Human Papilloma Virus (Types 16 and 18) vaccine - 2 dose vial	GlaxoSmithKline Biologicals	Gavi73*										\$4.6000	\$4.6000	\$4.6000	\$4.6000	\$4.6000	\$4.6000	\$4.6000	\$4.6000	\$4.6000	\$5.1800
GlaxoSmithKline Biologicals**	GNI per capita < \$3,995																		\$10.2500 - \$11.4000	\$10.2500 - \$11.4000	\$10.2500 - \$11.4000	\$10.2500		
GlaxoSmithKline Biologicals**	GNI per capita > \$3,995																		\$14.1400	\$14.1400	\$14.1400	\$14.1400		
Quadravalent Human Papilloma Virus (Types 6, 11, 16 and 18) vaccine - 1 dose vial	Merck Sharpe and Dome Corp	Gavi73*										\$4.5000	\$4.5000	\$4.5000	\$4.5000	\$4.5000	\$4.5000	\$4.5000	\$4.5000	\$4.5000	\$4.5000	\$4.5000	\$4.5000	\$4.5000
	Merck Sharpe and Dome Corp***	MICs														\$13.4000	\$13.4000	\$13.4000 - \$25.0000	\$13.4000 - \$25.0000	\$14.3400 - \$26.7500	\$14.3400 - \$26.7500	\$14.3400 - \$26.7500	\$14.3400 - \$26.7500	\$14.3400 - \$26.7500

Data shows awarded price per dose in US\$ per product per supplier per calendar year, based on supply agreement.

Prices displayed are in response to tenders with FCA incoterms.

\*Prices apply to Gavi-eligible and transitioning countries as listed on Gavi's website at <https://www.gavi.org/types-support/sustainability/eligibility> and <https://www.gavi.org/types-support/sustainability/transition>

\*\* Prices are applicable to the following non-Gavi Middle-Income Countries: Pacific Island Countries and Cape Verde

\*\*\* Prices are applicable to the following non-Gavi Middle-Income Countries: Botswana, Maldives, Seychelles and Turkmenistan.

Last updated 25th September 2020.